|
[1] PATEL VC,WHITE H,STY S,et al. Clinical science workshop:Targeting the gut-liver-brain axis[J]. Metab Brain Dis,2016,31(6):1327-1337.
|
|
[2] VILSTRUP H,AMODIO P,BAJAJ J,et al. Hepatic encephalopathy in chronic liver disease:2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver[J]. Hepatology,2014,60(2):715-735.
|
|
[3] DAM G,AAMANN L,VISTRUP H,et al. The role of branched chain amino acids in the treatment of hepatic encephalopathy[J]. J Clin Exp Hepatol,2018,8(4):448-451.
|
|
[4] QIN J,LI R,RAES J,et al. A human gut microbial gene catalogue established by metagenomic sequencing[J]. Nature,2010,464(7285):59-65.
|
|
[5] Human Microbiome Project Consortium. A framework for human microbiome research[J]. Nature,2012,486(7402):215-221.
|
|
[6] GALLAND L. The gut microbiome and the brain[J]. J Med Food,2014,17(12):1261-1272.
|
|
[7] ECKBURG PB,BIK EM,BERNSTEIN CN,et al. Diversity of the human intestinal microbial flora[J]. Science,2005,308(5728):1635-1638.
|
|
[8] DAVID LA,MAURICE CF,CARMODY RN,et al. Diet rapidly and reproducibly alters the human gut microbiome[J]. Nature,2014,505(7484):559-563.
|
|
[9] YATSUNENKO T,REY FE,MANARY MJ,et al. Human gut microbiome viewed across age and geography[J]. Nature,2012,486(7402):222-227.
|
|
[10] LIU Q,DUAN ZP,HA DK,et al. Synbiotic modulation of gut flora:Effect on minimal hepatic encephalopathy in patients with cirrhosis[J]. Hepatology,2004,39(5):1441-1449.
|
|
[11] ZHANG Z,ZHAI H,GENG J,et al. Large-scale survey of gut microbiota associated with MHE via 16S rRNA-based pyrosequencing[J]. Am J Gastroenterol,2013,108(10):1601-1611.
|
|
[12] BAJAJ JS,RIDLON JM,HYLEMON PB,et al. Linkage of gut microbiome with cognition in hepatic encephalopathy[J]. Am J Physiol Gastrointest Liver Physiol,2012,302(1):g168-g175.
|
|
[13] AHLUWALIA V,BETRAPALLY NS,HYLEMON PB,et al. Impaired gut-liver-brain axis in patients with cirrhosis[J]. Sci Rep,2016,6:26800.
|
|
[14] SUNG CM,LIN YF,CHEN KF,et al. Predicting clinical outcomes of cirrhosis patients with hepatic encephalopathy from the fecal microbiome[J]. Cell Mol Gastroenterol Hepatol,2019,8(2):301-318.
|
|
[15] DASANI BM,SIGAL SH,LIEBER CS. Analysis of risk factors for chronic hepatic encephalopathy:The role of helicobacter pylori infection[J]. Am J Gastroenterol,1998,93(5):726-731.
|
|
[16] HUBER M,RSSLE M,SIEGERSTETTER V,et al. Helicobacter pylori infection does not correlate with plasma ammonia concentration and hepatic encephalopathy in patients with cirrhosis[J].Hepatogastroenterology,2001,48(38):541-544.
|
|
[17] NAVA GM,STAPPENBECK TS. Diversity of the autochthonous colonic microbiota[J]. Gut Microbes,2011,2(2):99-104.
|
|
[18] CLARKE G,STILLING RM,KENNEDY PJ,et al. Minireview:Gut microbiota:The neglected endocrine organ[J]. Mol Endocrinol,2014,28(8):1221-1238.
|
|
[19] LYTE M. Microbial endocrinology in the microbiome-gutbrain axis:How bacterial production and utilization of neurochemicals influence behavior[J]. PLo S Pathog,2013,9(11):e1003726.
|
|
[20] PONZETTO A,VAIRA D. Hepatic encephalopathy and helicobacter pylori[J]. Dig Dis Sci,2018,63(5):1368-1369.
|
|
[21] JIAO N,BAKER SS,CHAPA-RODRIGUEZ A,et al. Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD[J]. Gut,2018,67(10):1881-1891.
|
|
[22] RIDLON JM,HARRIS SC,BHOWMIK S,et al. Consequences of bile salt biotransformations by intestinal bacteria[J]. Gut Microbes,2016,7(1):22-39.
|
|
[23] WANG Q,WANG B,SAXENA V,et al. The gut-liver axis:Impact of a mouse model of small-bowel bacterial overgrowth[J]. J Surg Res,2018,221:246-256.
|
|
[24] AGUIRRE VALADEZ JM,RIVERA-ESPINOSA L,MNDEZGUERRERO O,et al. Intestinal permeability in a patient with liver cirrhosis[J]. Ther Clin Risk Manag,2016,12:1729-1748.
|
|
[25] SPADONI I,ZAGATO E,BERTOCCHI A,et al. A gut-vascular barrier controls the systemic dissemination of bacteria[J].Science,2015,350(6262):830-834.
|
|
[26] GAUTREAUX MD,DEITCH EA,BERG RD. Bacterial translocation from the gastrointestinal tract to various segments of the mesenteric lymph node complex[J]. Infect Immun,1994,62(5):2132-2134.
|
|
[27] CHIEPPA M,RESCIGNO M,HUANG AY,et al. Dynamic imaging of dendritic cell extension into the small bowel lumen in response to epithelial cell TLR engagement[J]. J Exp Med,2006,203(13):2841-2852.
|
|
[28] NIESS JH,BRAND S,GU X,et al. CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance[J]. Science,2005,307(5707):254-258.
|
|
[29] FARACHE J,KOREN I,MILO I,et al. Luminal bacteria recruit CD103+dendritic cells into the intestinal epithelium to sample bacterial antigens for presentation[J]. Immunity,2013,38(3):581-595.
|
|
[30] FUNG TC,BESSMAN NJ,HEPWORTH MR,et al. Lymphoid-tissue-resident commensal bacteria promote members of the IL-10 cytokine family to establish mutualism[J]. Immunity,2016,44(3):634-646.
|
|
[31] DORAN KS,BANERJEE A,DISSON O,et al. Concepts and mechanisms:Crossing host barriers[J]. Cold Spring Harb Perspect Med,2013,3(7):a010090.
|
|
[32] HILDEBRAND GJ,WOLOCHOW H. Translocation of bacteriophage across the intestinal wall of the rat[J]. Proc Soc Exp Biol Med,1962,109:183-185.
|
|
[33] BAJAJ JS,HEUMAN DM,HYLEMON PB,et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications[J]. J Hepatol,2014,60(5):940-947.
|
|
[34] MORATALLA A,AMPUERO J,BELLOT P,et al. Lactulose reduces bacterial DNA translocation,which worsens neurocognitive shape in cirrhotic patients with minimal hepatic encephalopathy[J]. Liver Int,2017,37(2):212-223.
|
|
[35] CHEN YF,LI LJ,CHEN CL. Intestinal bacterial translocation and cirrhosis[J]. Chin J Pract Intern Med,2007,27(19):1545-1547.(in Chinese)陈燕飞，李兰娟，陈春雷．肠道细菌移位与肝硬化[J]．中国实用内科杂志，2007,27(19):1545-1547.
|
|
[36] MIHARA T,OTSUBO W,HORIGUCHI K,et al. The anti-inflammatory pathway regulated via nicotinic acetylcholine receptors in rat intestinal mesothelial cells[J]. J Vet Med Sci,2017,79(11):1795-1802.
|
|
[37] HANSLIN K,SJLIN J,SKORUP P,et al. The impact of the systemic inflammatory response on hepatic bacterial elimination in experimental abdominal sepsis[J]. Intensive Care Med Exp,2019,7(1):52.
|
|
[38] BUTTERWORTH RF. The liver-brain axis in liver failure:Neuroinflammation and encephalopathy[J]. Nat Rev Gastroenterol Hepatol,2013,10(9):522-528.
|
|
[39] LICINIO J,WONG ML. Pathways and mechanisms for cytokine signaling of the central nervous system[J]. J Clin Invest,1997,100(12):2941-2947.
|
|
[40] JIANG W,DESJARDINS P,BUTTERWORTH RF. Cerebral inflammation contributes to encephalopathy and brain edema in acute liver failure:Protective effect of minocycline[J]. J Neurochem,2009,109(2):485-493.
|
|
[41] VAQUERO J,POLSON J,CHUNG C,et al. Infection and the progression of hepatic encephalopathy in acute liver failure[J]. Gastroenterology,2003,125(3):755-764.
|
|
[42] TANG SH,CHEN H,HAN GH. Association between gut microbiota and hepatic encephalopathy in patients with liver cirrhosis[J]. J Clin Hepatol,2019,35(5):1109-1113.(in Chinese)汤世豪，陈辉，韩国宏．肠道菌群与肝硬化肝性脑病的关系[J]．临床肝胆病杂志，2019,35(5):1109-1113.
|
|
[43] BAJAJ JS. Hepatic encephalopathy:Classification and treatment[J]. J Hepatol,2018,68(4):838-839.
|
|
[44] BAJAJ JS,KHORUTS A. Microbiota changes and intestinal microbiota transplantation in liver diseases and cirrhosis[J]. J Hepatol,2020,72(5):1003-1027.
|
|
[45] HUDSON M,SCHUCHMANN M. Long-term management of hepatic encephalopathy with lactulose and/or rifaximin:A review of the evidence[J]. Eur J Gastroenterol Hepatol,2019,31(4):434-450.
|
|
[46] FENG L,PING CX,ZHANG L,et al. Observation on the efficacy of rifampicin in the treatment of liver cirrhosis encephalopathy[J].Beijing Med J,2017,39(9):965-966.(in Chinese)封莉，平春霞，张丽，等．利福昔明治疗肝硬化肝性脑病的疗效观察[J]．北京医学，2017,39(9):965-966.
|
|
[47] KALAMBOKIS G,TSIANOS EV. Endotoxaemia in the pathogenesis of cytopenias in liver cirrhosis. Could oral antibiotics raise blood counts?[J]. Med Hypotheses,2011,76(1):105-109.
|
|
[48] CHAUTANT F,GUILLAUME M,ROBIC MA,et al. Lessons from“real life experience”of rifaximin use in the management of recurrent hepatic encephalopathy[J]. World J Hepatol,2020,12(1):10-20.
|
|
[49] BAJAJ JS,HEUMAN DM,SANYAL AJ,et al. Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy[J]. PLo S One,2013,8(4):e60042.
|
|
[50] ELWIR S,RAHIMI RS. Hepatic encephalopathy:An update on the pathophysiology and therapeutic options[J]. J Clin Transl Hepatol,2017,5(2):142-151.
|
|
[51] LI M,WANG B,ZHANG M,et al. Symbiotic gut microbes modulate human metabolic phenotypes[J]. Proc Natl Acad Sci U S A,2008,105(6):2117-2122.
|
|
[52] SPENCER MD,HAMP TJ,REID RW,et al. Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency[J].Gastroenterology,2011,140(3):976-986.
|
|
[53] SHA W,da COSTA KA,FISCHER LM,et al. Metabolomic profiling can predict which humans will develop liver dysfunction when deprived of dietary choline[J]. FASEB J,2010,24(8):2962-2975.
|
|
[54] MURRAY M,ZALUZNY L,FARRELL GC. Drug metabolism in cirrhosis. Selective changes in cytochrome P-450 isozymes in the choline-deficient rat model[J]. Biochem Pharmacol,1986,35(11):1817-1824.
|
|
[55] DREKONJA D,REICH J,GEZAHEGN S,et al. Fecal microbiota transplantation for clostridium difficile infection:A systematic review[J]. Ann Intern Med,2015,162(9):630-638.
|
|
[56] KAO D,ROACH B,PARK H,et al. Fecal microbiota transplantation in the management of hepatic encephalopathy[J].Hepatology,2016,63(1):339-340.
|
|
[57] MEHTA R,KABRAWALA M,NANDWANI S,et al. Preliminary experience with single fecal microbiota transplant for treatment of recurrent overt hepatic encephalopathy-A case series[J].Indian J Gastroenterol,2018,37(6):559-562.
|
|
[58] BAJAJ JS,SALZMAN NH,ACHARYA C,et al. Fecal Microbial transplant capsules are safe in hepatic encephalopathy:A phase 1,randomized,placebo-controlled trial[J]. Hepatology,2019,70(5):1690-1703.
|
|
[59] WANG WW,ZHANG Y,HUANG XB,et al. Fecal microbiota transplantation prevents hepatic encephalopathy in rats with carbon tetrachloride-induced acute hepatic dysfunction[J].World J Gastroenterol,2017,23(38):6983-6994.
|
DownLoad: